The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial
Open accessAbstract
enalapril ◼ heart failure ◼ hospitalization ◼ valsartan I n outpatients with chronic heart failure (HF) with reduced ejection fraction known to tolerate an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, substitution of the angiotensin-neprilysin inhibitor sacubitril/valsartan reduces the rate of cardiovascular death or HF hospitalization. 1 Accordingly, consensus guidelines recommend the use of sacubitril/valsartan to treat patients with symptomatic HF with reduced ejection fraction.2 Until recently, however, the efficacy and safety of sacubitril/valsartan among patients hospitalized for acute decompensated heart failure (ADHF) was unknown.We have reported the primary results of the randomized double-blind PIONEER-HF trial (Comparison of Sacubitril-Valsartan versus Enalapril on Effect on NT-proBNP in Patients Stabilized from an Acute Heart Failure Episode) demonstrating that, in comparison with enalapril, in patients hemodynamically stabilized during hospitalization for ADHF, sacubitril/ valsartan achieved a greater reduction in N-terminal pro-brain natriuretic peptide concentration, was safe and well-tolerated, and was associated with a significant reduction in the serious composite clinical end point of death, rehospitalization for HF, implantation of a left ventricular assist device, or listing for cardiac transplantation (hazard ratio, 0.54; 95% CI, 0.37-0.79).3 By design, 4 our previously reported analyses of clinical end points relied on investigator-reported data.We undertook an exploratory analysis of the end point of cardiovascular death or rehospitalization for HF to assess the consistency with the results of the pivotal trial in chronic HF. 1 A post hoc adjudication of rehospitalization for HF and cause of death according to standardized definitions 1,5 was performed by the same blinded clinical events committee (CEC) for rigorous confirmation of these end points.In this research letter, we report the results of these additional analyses from PIONEER-HF.PIONEER-HF was an 8-week multicenter, randomized, double-blind, doubledummy, active-controlled trial of in-hospital initiation of sacubitril/valsartan in comparison with enalapril in patients stabilized during hospitalization for ADHF. 4 Eligible patients were to have a left ventricular ejection fraction ≤40% and signs and symptoms of HF along with an N-terminal pro-brain natriuretic peptide concentration ≥1600 pg/mL or brain natriuretic peptide concentration ≥400 pg/mL.Patients were enrolled ≥24 hours and up to 10 days after presentation while still hospitalized and were to be hemodynamically stable using protocol-defined criteria.4 Institutional review boards approved the protocol at all sites.All participants provided written informed consent.We evaluated the cumulative incidence of the adjudicated prespecified exploratory clinical composite end point of death from any cause, rehospitalization for HF, left ventricular assist device implantation, or listing for cardiac transplant, and the composite of cardiovascular death or rehospitalization for HF, as well.Adjudication of death and rehospitalization for HF was performed by a CEC blinded to
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationYancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
Angiotensin-neprilysin inhibition in acute decompensated heart failure
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812851 · Cited by 1,260
Self-citation2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citation
Cited by
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
Heart Failure With Reduced Ejection Fraction: A Review
Murphy, S. P., Ibrahim, N. E., & Januzzi, J. L. (2020) · JAMA · doi:10.1001/jama.2020.10262 · Cited by 769
DeVore, A. D., Braunwald, E., Morrow, D. A., Duffy, C. I., Ambrosy, A. P., Chakraborty, H., McCague, K., Rocha, R., Velazquez, E. J., & for the PIONEER-HF Investigators (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4665 · Cited by 87
Self-citationPascual-Figal, D., Wachter, R., Senni, M., Bao, W., Noè, A., Schwende, H., Butylin, D., Prescott, M. F., Gniot, J., Mozheiko, M., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.05.012 · Cited by 38
Metadata
- Authors
- Morrow, D. A., Velazquez, E. J., DeVore, A. D., Desai, A. S., Duffy, C. I., Ambrosy, A. P., Gurmu, Y., McCague, K., Rocha, R., & Braunwald, E.
- Venue
- Circulation
- Published
- 2019-05-07
- Volume
- 139
- Issue
- 19
- Pages
- 2285-2288
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2938564873
- Cited by
- 170
- References
- 4
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. https://app.cochat.ai/papers/10.1161/circulationaha.118.039331
- The paper
- Morrow, D. A., Velazquez, E. J., DeVore, A. D., Desai, A. S., Duffy, C. I., Ambrosy, A. P., Gurmu, Y., McCague, K., Rocha, R., & Braunwald, E. (2019). Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation. https://doi.org/10.1161/circulationaha.118.039331
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.